הכנסה תפעולית לפני ניכוי פחת: SciSparc Ltd. (SPRC)

SciSparc Ltd develops cannabinoid-based treatments for brain pathologies, reducing drug dosages while maintaining efficacy. The absolute cash result of operations reflects current profit trends, with the indicator holding around 0.00. The company relies on low demand elasticity within the CannAmide niche, yet faces risks due to the complexity of CNS tests and investments in third-party consumer assets.

As a biopharmaceutical startup in the clinical trial stage, SciSparc Ltd (SPRC) has no commercial sales, which makes the annual EBITDA figure a reflection solely of the capital burn rate. While this metric captures the business's daily ability to generate cash from operations, for this issuer, it serves as a cash burn indicator, warning investors of the risks of a sharp price correction once liquidity is exhausted.